Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds

Fabio Pagella, Elina Matti, Francesco Chu, Alessandro Pusateri, Carmine Tinelli, Carla Olivieri, Cecilia Canzonieri, Laura Boeri, Federica Ornati, Cesare Danesino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Conclusions: In contrast to the current trend according to which the treatment of hereditary hemorrhagic telangiectasia (HHT) epistaxis depends on clinical severity, argon plasma coagulation (APC) has also proven to be effective as a first-line procedure in patients with severe nosebleeds. Furthermore, with this approach patients are free from requirements for blood transfusions for a long time in the vast majority of cases. Objective: The aim of this study was to test the efficacy of APC treatment as a first-line procedure in HHT patients affected by severe epistaxis. Methods: From 1996 until 2011, 252 HHT patients were treated with APC in our clinic. We selected 26 patients with severe epistaxis for whom the need for blood transfusion had been recorded. This group of patients was asked to answer a questionnaire that aimed to evaluate the severity of epistaxis (defined by its intensity, frequency, and duration), to assess the duration of the benefit of treatment and to evaluate the number of blood transfusions required before and after treatment. Results: After APC treatment, a statistically significant decrease in all epistaxis parameters was recorded and most patients did not need blood transfusions for several years after the procedure.

Original languageEnglish
Pages (from-to)174-180
Number of pages7
JournalActa Oto-Laryngologica
Volume133
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Argon Plasma Coagulation
Hereditary Hemorrhagic Telangiectasia
Epistaxis
Blood Transfusion
Therapeutics

Keywords

  • Blood transfusion
  • Endoscopic
  • Epistaxis
  • HHT
  • Mini-invasive
  • Quality of life
  • Rendu-Osler-Weber syndrome

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds. / Pagella, Fabio; Matti, Elina; Chu, Francesco; Pusateri, Alessandro; Tinelli, Carmine; Olivieri, Carla; Canzonieri, Cecilia; Boeri, Laura; Ornati, Federica; Danesino, Cesare.

In: Acta Oto-Laryngologica, Vol. 133, No. 2, 02.2013, p. 174-180.

Research output: Contribution to journalArticle

@article{99dd7529da454b6db4d54de48fbc80b3,
title = "Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds",
abstract = "Conclusions: In contrast to the current trend according to which the treatment of hereditary hemorrhagic telangiectasia (HHT) epistaxis depends on clinical severity, argon plasma coagulation (APC) has also proven to be effective as a first-line procedure in patients with severe nosebleeds. Furthermore, with this approach patients are free from requirements for blood transfusions for a long time in the vast majority of cases. Objective: The aim of this study was to test the efficacy of APC treatment as a first-line procedure in HHT patients affected by severe epistaxis. Methods: From 1996 until 2011, 252 HHT patients were treated with APC in our clinic. We selected 26 patients with severe epistaxis for whom the need for blood transfusion had been recorded. This group of patients was asked to answer a questionnaire that aimed to evaluate the severity of epistaxis (defined by its intensity, frequency, and duration), to assess the duration of the benefit of treatment and to evaluate the number of blood transfusions required before and after treatment. Results: After APC treatment, a statistically significant decrease in all epistaxis parameters was recorded and most patients did not need blood transfusions for several years after the procedure.",
keywords = "Blood transfusion, Endoscopic, Epistaxis, HHT, Mini-invasive, Quality of life, Rendu-Osler-Weber syndrome",
author = "Fabio Pagella and Elina Matti and Francesco Chu and Alessandro Pusateri and Carmine Tinelli and Carla Olivieri and Cecilia Canzonieri and Laura Boeri and Federica Ornati and Cesare Danesino",
year = "2013",
month = "2",
doi = "10.3109/00016489.2012.718097",
language = "English",
volume = "133",
pages = "174--180",
journal = "Acta Oto-Laryngologica",
issn = "0001-6489",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds

AU - Pagella, Fabio

AU - Matti, Elina

AU - Chu, Francesco

AU - Pusateri, Alessandro

AU - Tinelli, Carmine

AU - Olivieri, Carla

AU - Canzonieri, Cecilia

AU - Boeri, Laura

AU - Ornati, Federica

AU - Danesino, Cesare

PY - 2013/2

Y1 - 2013/2

N2 - Conclusions: In contrast to the current trend according to which the treatment of hereditary hemorrhagic telangiectasia (HHT) epistaxis depends on clinical severity, argon plasma coagulation (APC) has also proven to be effective as a first-line procedure in patients with severe nosebleeds. Furthermore, with this approach patients are free from requirements for blood transfusions for a long time in the vast majority of cases. Objective: The aim of this study was to test the efficacy of APC treatment as a first-line procedure in HHT patients affected by severe epistaxis. Methods: From 1996 until 2011, 252 HHT patients were treated with APC in our clinic. We selected 26 patients with severe epistaxis for whom the need for blood transfusion had been recorded. This group of patients was asked to answer a questionnaire that aimed to evaluate the severity of epistaxis (defined by its intensity, frequency, and duration), to assess the duration of the benefit of treatment and to evaluate the number of blood transfusions required before and after treatment. Results: After APC treatment, a statistically significant decrease in all epistaxis parameters was recorded and most patients did not need blood transfusions for several years after the procedure.

AB - Conclusions: In contrast to the current trend according to which the treatment of hereditary hemorrhagic telangiectasia (HHT) epistaxis depends on clinical severity, argon plasma coagulation (APC) has also proven to be effective as a first-line procedure in patients with severe nosebleeds. Furthermore, with this approach patients are free from requirements for blood transfusions for a long time in the vast majority of cases. Objective: The aim of this study was to test the efficacy of APC treatment as a first-line procedure in HHT patients affected by severe epistaxis. Methods: From 1996 until 2011, 252 HHT patients were treated with APC in our clinic. We selected 26 patients with severe epistaxis for whom the need for blood transfusion had been recorded. This group of patients was asked to answer a questionnaire that aimed to evaluate the severity of epistaxis (defined by its intensity, frequency, and duration), to assess the duration of the benefit of treatment and to evaluate the number of blood transfusions required before and after treatment. Results: After APC treatment, a statistically significant decrease in all epistaxis parameters was recorded and most patients did not need blood transfusions for several years after the procedure.

KW - Blood transfusion

KW - Endoscopic

KW - Epistaxis

KW - HHT

KW - Mini-invasive

KW - Quality of life

KW - Rendu-Osler-Weber syndrome

UR - http://www.scopus.com/inward/record.url?scp=84872362189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872362189&partnerID=8YFLogxK

U2 - 10.3109/00016489.2012.718097

DO - 10.3109/00016489.2012.718097

M3 - Article

C2 - 23066781

AN - SCOPUS:84872362189

VL - 133

SP - 174

EP - 180

JO - Acta Oto-Laryngologica

JF - Acta Oto-Laryngologica

SN - 0001-6489

IS - 2

ER -